UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 9, 2024

Pulse Biosciences, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) **001-37744** (Commission File Number)

46-5696597 (IRS Employer Identification No.)

3957 Point Eden Way

Hayward, California 94545 (Address of Principal Executive Offices) (Zip Code)

ess of Finicipal Executive Offices) (Zip Co

<u>510-906-4600</u>

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
	Common stock, \$0.001 par value per share	PLSE	The Nasdaq Stock Market
- 5		1 1 0 1 1 1 1 4	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 **Regulation FD Disclosure.**

On January 9, 2024, Pulse Biosciences, Inc., a Delaware corporation (the "Company"), posted an updated investor presentation on its website. The updated investor presentation (the "Investor Deck") discloses recent progress in the Company's ongoing product development programs relating to its proprietary CellFXTM nsPFATM 360 Cardiac Catheter, its CellFX nsPFA Cardiac Clamp, and its CellFX nsPFA Percutaneous Electrode. The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company's website at www.pulsebiosciences.com under "Investors."

Except for the Investor Deck, information contained on, or accessible through, the Company's website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company's filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of January 2024, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.

The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.

Item 9.01	Financial Statements and Exhibits.
(d) Exhibits	
<u>Exhibit</u> <u>Number</u>	Description
99.1 104	Investor Deck, dated January 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PULSE BIOSCIENCES, INC.

Date: January 9, 2024

By: /s/ Kevin P. Danahy

Kevin P. Danahy President and Chief Executive Officer (Principal Executive and Principal Financial Officer)






Investor Presentation

January 2024

Forward Looking Statements

All statements in this presentation that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company's expected product development efforts, statements concerning the Company's future regulatory strategies and possible government clearances and approvals, statements concerning the Company's future regulatory strategies and possible government clearances and approvals, statements concerning the Company's future regulatory strategies and possible government clearances and approvals, statements concerning customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation and benign thyroid nodules, statements about the Company's future financing opportunities and operating expenses, and Pulse Biosdences' expectations, whether stated or implied, regarding whether future dinical studies will show the CellFX System to address a range of condition, such as their future events. These statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates," and other similar or related expressions are used to identify these forward-looking statements, and swipptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company's fillings with the U.S. Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this pre

Pulse Biosciences



Powering the next generation in bioelectric medicine with **Nanosecond Pulsed Field Ablation** technology.



Pulse Biosciences

Proven Leadership Team



Accelerated Clinical Progress with CellFX nsPFA Devices




Positioned to Unlock the \$8 Billion Cardiac Atrial Fibrillation (AF) Market

Powering the next generation in bioelectric medicine with Nanosecond Pulsed Field Ablation (nsPFA) Technology



Addressing the Entirety of the Growing AF Market



Pulse Biosciences[•]

Norther, Measure providence, Nex Meth, Cause, BJA, Admuil finitiations and future, (Accessed August 24, 2021) Web 24 Annual Measure 2021 Web 24 Annual Measure 2021 © 2023-24 Public Biosciences, Inc. All rights reserved. Speenheimer Report 2020

7

Differentiated Properties of nsPFA Energy Pulses



Nanosecond pulses can be ~500 times shorter than microsecond pulses


As a result, nsPFA can require ~20 times less energy to ablate cardiac tissue

Pulse Biosciences ² nsPFA uses a <u>nanosecond pulse</u> of higher amplitude and significantly shorter duration		Standard PFA devices coming to market use RF-Style designs and off-the-shelf generators that are not designed specifically for cardiac PFA applications	
		A uses longer, low amplitude ting in high total energy delivery	
	~		

Pulse Biosciences[•]

Advantages of nsPFA Technology

Catheter and clamp devices designed to improve patient outcomes



9


Open Surgical Delivery of nsPFA Energy – Cardiac Ablation



- A nonthermal cardiac ablation clamp capable of complete transmural ablations in under 3 seconds
- Initial preclinical studies have demonstrated speed, precision and transmurality up to ~25mm between electrodes
- · Collaborating with top institutions and physicians in pursuit of regulatory clearance
- Fundamental IP for nsPFA energy in cardiac ablation

6	Pulse Riosciences	ulse Biosciences' 1) 2-Day Histology: Gomori trichrome stain showing treated tissue through the left atrial appendage in a porcine		
	Fuise biosciences	 2-Day Histology: Gomori trichrome stain showing treated tissue through the left atrial appendage in a porcine model 	©2023-24Pulse Biosciences, Inc. All rights reserved.	10

Cardiac Clamp Strategic Opportunity



Pulse Biosciences^a 1) AtriCure 2022 Annual Report 2) Oppenheimer Market Research 2020

Catheter Delivery of nsPFA Energy – Cardiac Ablation






2-Day Endocardial Surface ~5cm Diameter

- Circumferential ablation catheter enabled by nsPFA energy for single-shot PVI ablation
- Reduced muscle spasm and nerve capture due to short duration nsPFA pulses
- No thermal injury due to lower energy of nsPFA pulses
- Preclinical data demonstrating safe, fast and effective ablations


Pulse Biosciences[•]

nsPFA Preclinical Evidence Supporting Safety, Tolerability and Effectiveness



Pulse Blosciences' proprietary Nanosecond Pulsed Field Ablation¹⁴⁴ (nsFFA¹⁴⁴) Technology was recently featured in multiple presentations at the 2023 Heart Rhythm Society Meeting (HRS 2023)

Application Milestones for Treatment of AF



Pulse Biosciences[•]

Versatile Generator Platform Delivers nsPFA Across the Anatomy

Enables rapid development of new applications

V

FDA 510k submission

filed November 2023

Thyroid

- Completed phase 1 enrollment of study, phase 2 in progress
- Preclinical and clinical data demonstrating safety to collateral structures including nerves, vessels, trachea & esophagus.
- Rapid ablation of thyroid tissue
 <10 seconds per cc of treated tissue
- Single treatment efficacy with evidence of 100% clearance within ablation zone in less than 90 days


Pulse Biosciences[•]

©2023-24Pulse Biosciences, Inc. All rights reserved.

15

Robust IP Portfolio

Wide and deep IP coverage of nsPFA energy & system





Pulse Biosciences[•]



Expect to be revenue-generating with 2 of 3 product lines in 2024



CellFX nsPFA cardiac ablation clamp – filed FDA 510(k) submission December 2023 with plans to commercialize following clearance



CellFX nsPFA cardiac ablation catheter – commenced first-in-human catheter ablation feasibility study in December 2023 with plans to expand enrollment



CellFX nsPFA percutaneous electrode – filed FDA 510(k) submission in November with plans to commercialize following clearance